drugset
Drugs / rhuFab V2
last change Jun 2021 re-read 3 minutes ago

rhuFab V2

also known as ranibizumab
Developed for
age-related macular degeneration
Investigated by
Genentech, Inc.

Trials 2

today NCT00056823 · Ph 1/2 NCT00056836 · Ph 3
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00056823 Mar 2003 → Dec 2005 age-related macular degeneration Genentech, Inc. Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT00056836 Mar 2003 → Dec 2005 age-related macular degeneration Genentech, Inc. Completed Met primary

Press releases naming this drug 10 releases

DateIssuerRelease
2021-06-23 Genentech, Inc. FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD) gene.com ↗
2020-07-22 Genentech, Inc. Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration gene.com ↗
2020-05-26 Genentech, Inc. Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration gene.com ↗
2018-07-25 Genentech, Inc. Genentech Unveils Positive Phase II Results for the Port Delivery System with Ranibizumab (PDS), the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD) gene.com ↗
2018-03-21 Genentech, Inc. FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy gene.com ↗
2017-04-17 Genentech, Inc. FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States gene.com ↗
2017-01-05 Genentech, Inc. FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization gene.com ↗
2016-10-14 Genentech, Inc. FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe gene.com ↗
2016-10-10 Genentech, Inc. FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization gene.com ↗
2015-02-06 Genentech, Inc. FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema gene.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as rhuFab V2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00056823 ↗
1

NCT00056836 ↗
Known as ranibizumab “rhuFab V2 (ranibizumab)” NCT00056823 ↗
1

“rhuFab V2 (ranibizumab)” NCT00056836 ↗
Route Intravitreal “Intravitreal Injections of rhuFab V2” NCT00056823 ↗